zoledronic acid has been researched along with Carcinoma, Lobular in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Clézardin, P; Lelièvre, L; Magaud, L; Mathevet, P; Mouret-Reynier, MA; Raban, N; Roche, L; Tigaud, JD; Topart, D; Tubiana-Mathieu, N | 1 |
| Cohen, PR | 1 |
| Friese, K; Janni, W; Rack, B; Schindlbeck, C; Sommer, H; Strobl, B | 1 |
1 review(s) available for zoledronic acid and Carcinoma, Lobular
| Article | Year |
|---|---|
Zoledronic acid-associated symmetrical drug-related intertriginous and flexural exanthema (SDRIFE): report of baboon syndrome in a woman with recurrent metastatic breast cancer after receiving zoledronic acid.
Topics: Arm; Axilla; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Buttocks; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Combined Modality Therapy; Diphosphonates; Drug Eruptions; Erythema; Female; Humans; Imidazoles; Intertrigo; Lung Neoplasms; Middle Aged; Mixed Tumor, Malignant; Syndrome; Zoledronic Acid | 2015 |
2 trial(s) available for zoledronic acid and Carcinoma, Lobular
| Article | Year |
|---|---|
Comparative Study of Neoadjuvant Chemotherapy With and Without Zometa for Management of Locally Advanced Breast Cancer With Serum VEGF as Primary Endpoint: The NEOZOL Study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Middle Aged; Neoadjuvant Therapy; Prognosis; Prospective Studies; Survival Rate; Vascular Endothelial Growth Factor A; Young Adult; Zoledronic Acid | 2018 |
[Efficacy of zoledronate in treating persisting isolated tumor cells in bone marrow in patients with breast cancer. A phase II pilot study].
Topics: Adult; Aged; Antineoplastic Agents; Bone Density Conservation Agents; Bone Marrow; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Combined Modality Therapy; Diphosphonates; Female; Humans; Imidazoles; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Hormone-Dependent; Pain; Pilot Projects; Prognosis; Zoledronic Acid | 2008 |